Stifel Maintains Buy on MapLight Therapeutics, Raises Price Target to $36
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Stifel analyst Paul Matteis maintains MapLight Therapeutics (NASDAQ:MPLT) with a Buy and raises the price target from $28 to $36.
Stifel analyst Paul Matteis maintains MapLight Therapeutics (NASDAQ:MPLT) with a Buy and raises the price target from $28 to $36.